NCT06793553View on ClinicalTrials.gov

Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

PHASE2RecruitingINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

September 30, 2028

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Induction therapy

2 cycles of PTX+ bevacizumab induction therapy followed by atezolizumab+nab-PTX

Trial Locations (1)

135-8550

RECRUITING

Yukinori Ozaki, Koto-ku, 3-8-31

Sponsors

Collaborators (1)

Chugai Pharmaceutical
All Listed Sponsors
collaborator

Chugai Pharmaceutical

INDUSTRY

lead

Japan Breast Cancer Research Group

OTHER